Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

BioMed Research International - United States
doi 10.1155/2018/1042597
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Direct Costs Associated With Relapsed Diffuse Large B‐Cell Lymphoma Therapies

Oncologist
Cancer ResearchMedicineOncology
2019English

Molecular Landscape of Relapse/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Ets1 Positively Regulates Faim3 in Activated B Cell-Like (Abc) Diffuse Large B Cell Lymphoma (Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology
Oncology
2019English

Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma

Seminars in Diagnostic Pathology
Forensic MedicinePathology
2011English

Diffuse Large B-Cell Lymphoma

2020English

The Proportion of Activated B-Cell Like Subtype Among De Novo Diffuse Large B-Cell Lymphoma Increases With Age

Haematologica
Hematology
2011English

Diffuse Large B-Cell Lymphoma Presenting With Cholecystitis-Like Symptoms

Korean Journal of Clinical Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy